Iran Injectable Products Company (DEFRA) income statement
Operating revenue through to net profit and earnings per share
- Ticker
- DEFRA
- Industry
- Pharmaceuticals
- Market
- Tehran Stock Exchange
Latest periods
| Item | To 1405/06/31 | To 1404/06/31 | To 1403/06/31 | To 1402/06/31 | To 1401/06/31 | To 1400/06/31 |
|---|---|---|---|---|---|---|
| Operating revenue | 27,965,616 | 11,895,496 | 5,739,285 | 5,054,915 | 3,526,586 | 2,328,311 |
| Cost of operating revenue | -5,934,562 | -4,027,027 | -1,788,644 | -1,610,777 | -1,141,804 | -748,889 |
| Gross profit (loss) | 22,031,054 | 7,868,469 | 3,950,641 | 3,444,138 | 2,384,782 | 1,579,422 |
| Selling, general and administrative expenses | -765,469 | -562,095 | -305,983 | -220,364 | -139,192 | -89,952 |
| Other income | 129,380 | 88,216 | 57,035 | 45,613 | 39,041 | 22,951 |
| Operating profit (loss) | 21,394,965 | 7,394,590 | 3,701,658 | 3,269,386 | 2,284,631 | 1,512,421 |
| Other non-operating income and expenses | 1,429,710 | 262,102 | 123,780 | 275,226 | 179,461 | 35,839 |
| Profit (loss) from continuing operations before tax | 22,824,675 | 7,656,692 | 3,825,438 | 3,544,612 | 2,464,092 | 1,548,260 |
| Current year tax | -4,813,895 | -1,659,617 | -833,567 | -735,598 | -554,420 | -338,431 |
| Net profit (loss) from continuing operations | 18,010,780 | 5,997,075 | 2,991,871 | 2,809,014 | 1,893,066 | 1,167,446 |
| Net profit (loss) | 18,010,780 | 5,997,075 | 2,991,871 | 2,809,014 | 1,893,066 | 1,167,446 |
| Basic earnings (loss) per share | 2,573 rials | 2,142 rials | 2,137 rials | 2,006 rials | 1,352 rials | 1,722 rials |
| Net earnings (loss) per share, rials | 2,573 rials | 2,142 rials | 2,138 rials | 2,007 rials | 1,353 rials | 1,668 rials |
| Capital | 7,000,000 | 2,800,000 | 1,400,000 | 1,400,000 | 1,400,000 | 700,000 |
Reporting periods
93 periods are on file for this report, from the period ending 1380/12/29 to the period ending 1405/06/31.